ECTRIMS 2017
Scientific Summaries

The 2017 European Committee for Treatment and Research for Multiple Sclerosis (ECTRIMS) annual meeting will be held at Le Palais des Congrès de Paris in France from October 25-28. We have selected a number of major presentations that have the potential to improve MS outcomes.

 

High Efficacy DMTs Reduce Relapses With Early Use

High Efficacy DMTs Reduce Relapses With Early Use

Should clinicians prescribe high efficacy DMTs for patients with RRMS shortly after diagnosis or reserve them for use once they develop resistance to first-line therapies? A new study from ECTRIMS 2017 may have found an answer.
Two Drugs Reduce Conversion to SPMS

Two Drugs Reduce Conversion to SPMS

New research presented at the 2017 ECTRIMS conference has identified two therapies that appear to extend or even prevent the time it takes for RRMS to transition to SPMS.
Biomarker Predicts Conversion From CIS to MS

Biomarker Predicts Conversion From CIS to MS

New research presented at the 2017 ECTRIMS conference indicates that a test of cerebrospinal fluid could identify which patients are greater risk of CIS to MS progression more accurately than current methods.
Siponimod Slows Progression in SPMS

Siponimod Slows Progression in SPMS

Recent research suggests a new immunomodulator could give these patients with secondary progressive multiple sclerosis (SPMS) another alternative to previous treatments.
New Therapy Found to be Safe and Effective for RRMS

New Therapy Found to be Safe and Effective for RRMS

Results of the RADIANCE trial indicate that a new therapy option for patients with RRMS may be on the horizon, according to a study presented at ECTRIMS 2017.
Education Level Predicts Memory Loss in Progressive MS

Education Level Predicts Memory Loss in Progressive MS

Researchers find an answer that helps explain cognitive impairment in patients with progressive multiple sclerosis.

New Analysis Supports Ocrelizumab Safety

New Analysis Supports Ocrelizumab Safety

Researchers presented updated safety information for ocrelizumab for patients with primary progressive MS or relapsing forms of the disease.

Could the Innate Immune System Provide a Pathway to Treat PPMS?

Could the Innate Immune System Provide a Pathway to Treat PPMS?

New ECTRIMS 2017 study finds that the innate immune system could play a critical role in the development of multiple sclerosis.
Intensive Neurorehabilitation Improves Treatment Outcomes in MS

Intensive Neurorehabilitation Improves Treatment Outcomes in MS

New ECTRIMS 2017 study finds that not treating depression and fatigue in neurorehabilitated patients with progressive multiple sclerosis could have dire consequences.